Patents Assigned to Action Pharma A/S
-
Patent number: 8058306Abstract: The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): (I) including tautomeric forms thereof, wherein n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.Type: GrantFiled: June 11, 2007Date of Patent: November 15, 2011Assignee: Action Pharma A/SInventors: Arne Boman, Thomas Engelbrecht Norkild Jonassen, Torbjorn Lundstedt
-
Publication number: 20110082183Abstract: The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): (I) including tautomeric forms thereof, wherein n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones.Type: ApplicationFiled: June 11, 2007Publication date: April 7, 2011Applicant: Action Pharma A/SInventors: Arne Boman, Thomas Engelbrecht Norkild Jonassen, Torbjorn Lundstedt
-
Patent number: 7662782Abstract: The invention relates to methods of treatment comprising administering a compound of the general formula (1): to a patient or a healthy individual.Type: GrantFiled: December 29, 2005Date of Patent: February 16, 2010Assignee: Action Pharma A/SInventors: Michael Szardenings, Ruta Muceniece, Ilze Mutule, Felikss Mutulis, Jarl Wikberg
-
Publication number: 20090069242Abstract: The invention describes peptide analogues of a-melanocyte-stimulating hormone (a-MSH), which posses an increased efficacy compared to the native ?-MSH peptide. The ?-MSH analogues exhibit increased anti-inflammatory effects and increased capability to prevent ischemic conditions compared to ?-MSH. The invention further discloses use of the peptides for the manufacture of pharmaceutical compositions for the treatment or prophylaxis of a condition in the tissue of one or more organs of a mammal, and moreover pharmaceutical compositions.Type: ApplicationFiled: August 26, 2005Publication date: March 12, 2009Applicant: ACTION PHARMA A/SInventors: Thomas E.N. Jonassen, Soren Nielsen, Jorgen Frokiaer, Bjarne Due Larsen
-
Publication number: 20090018183Abstract: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.Type: ApplicationFiled: September 17, 2008Publication date: January 15, 2009Applicant: ACTION PHARMA A/SInventors: Torbjorn Lundstedt, Anna Skottner, Arne Boman, Per Andersson, Elisabeth Seifert, Victor Andrianov
-
Patent number: 7442807Abstract: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.Type: GrantFiled: March 15, 2006Date of Patent: October 28, 2008Assignee: Action Pharma A/SInventors: Torbjörn Lundstedt, Anna Skottner, Arne Boman, Per Andersson, Elisabeth Seifert, Victor Andrianov
-
Patent number: 7186748Abstract: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.Type: GrantFiled: August 6, 2002Date of Patent: March 6, 2007Assignee: Action Pharma A/SInventors: Torbjörn Lundstedt, Anna Skottner, Arne Boman, Per Andersson, Elisabeth Seifert, Victor Andrianov
-
Publication number: 20060148798Abstract: The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: wherein X is (CH2)n where n is 0, 1 or 2; R1, R2, R3, R4 and R5 may be the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, alkylsulphonyloxy, cyano, nitro, trihaloalkyl, sulpho or one of the structures given in Scheme 1; or two of R1, R2, R3, R4 and R5 may together form a methylenedioxy or ethylenedioxy moiety; R6, R7, R8 and R9 are the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, alkoxy having 1 to 5 carbon atoms, hydroxy, amines (primary, secondary or tertiary) having 0, 1 or 2 carbon atoms, cyano, nitro, trihaloalkyl, amide or sulpho, and z where shown represents the point of attachment of the residue to the phenyl or pyrrole ring; and the pharmacologically active salts thereof.Type: ApplicationFiled: March 15, 2006Publication date: July 6, 2006Applicant: ACTION PHARMA A/SInventors: Torbjorn Lundstedt, Anna Skottner, Arne Boman, Per Andersson, Elisabeth Seifert, Victor Andrianov
-
Patent number: 7008925Abstract: A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH2X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.Type: GrantFiled: May 5, 1999Date of Patent: March 7, 2006Assignee: Action Pharma A/SInventors: Michael Szardenings, Ruta Muceniece, Ilze Mutule, Felikss Mutulis, Jarl Wikberg